DYNAVAX TECHNOLOGIES CORP
DVAXHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $277.2M | $232.3M | $722.7M | $439.4M | $46.6M | $35.2M |
| Operating income | −$4.1M | −$37.0M | $283.5M | $134.5M | −$68.4M | −$134.8M |
| Net income | $27.3M | −$6.4M | $293.2M | $76.7M | −$75.2M | −$152.6M |
| Total assets | $986.3M | $997.1M | $985.9M | $1.04B | $353.3M | $279.1M |
| Total liabilities | $389.5M | $375.0M | $404.8M | $816.9M | $294.6M | $270.8M |
| Equity | $596.8M | $622.1M | $581.0M | $222.4M | $58.7M | $8.3M |
| EPS (diluted) | $0.20 | $-0.05 | $1.97 | $0.57 | $-0.78 | $-2.16 |
| Shares out. | 130.6M | 127.7M | 124.9M | 113.3M | 86.2M | 64.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −1.5%
- Net margin
- 9.9%
- Return on equity
- 4.6%
- Return on assets
- 2.8%
- Return on capital (ROCE)
- −0.5%
- Liabilities / assets
- 39.5%
- Debt / equity
- 0.65×
- Book value / share
- $4.57
- Revenue growth (YoY)
- 19.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- 3.72safe
- Accruals / assets
- −4.0%clean
- Piotroski F-Score
- 6/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 5 good- Operating losses (negative operating margin)
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Recruitingreadout ~2026-05-29Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
- Phase 1/2Active Not Recruitingreadout ~2027-11Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Deep Track Capital, LpActivist (13D)Feb 11, 2026
- Blackrock, Inc.Passive (13G)Jul 17, 2025
- Kynam Capital Management, LpPassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Jan 30, 2026 | 9.8M | 5.2 | +7.3% |
| Jan 15, 2026 | 9.1M | 1.8 | -14.0% |
| Dec 31, 2025 | 10.6M | 1.9 | -13.6% |
| Dec 15, 2025 | 12.3M | 8.0 | -14.0% |
| Nov 28, 2025 | 14.3M | 8.7 | +4.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsFeb 10, 2026
- Entered a material agreement · Director / officer change · Regulation FD disclosureDec 29, 2025
- Results of operationsNov 5, 2025
- Director / officer changeOct 16, 2025
- Regulation FD disclosureAug 21, 2025
- Results of operationsAug 7, 2025
- Modified shareholder rights · Amended charter or bylaws · Shareholder voteJun 17, 2025
- Director / officer changeMay 13, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.